Compare Figs Inc (FIGS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Neurocrine Biosciences Inc — how do they compare? Figs Inc trades at $10.14 (market cap $1.66B), while Neurocrine Biosciences Inc trades at $171.81 (market cap $17.30B). The key difference: Neurocrine Biosciences Inc is far larger — about 10.4× Figs Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| FIGS | NBIX | |
|---|---|---|
Market Cap | $1.66B | $17.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $180.55 |
52-Week Low | $5.81 | $123.10 |
Enterprise Value | $1.44B | $16.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $9.72, down 2.8% today, amid bearish technical signals despite recent earnings beats. Revenue grew to $631M in 2025 with a 66.6% gross margin, but net cash flow remains negative. Analyst consensus is bullish with a $19.50 price target, though technical indicators show selling pressure with RSI at neutral levels and ADX signaling a strong downtrend.
The stock presents a growth opportunity with strong fundamentals and analyst support, but faces near-term technical headwinds and margin pressures from tariffs and freight costs. Investors should weigh the 100% upside to consensus target against execution risks and persistent negative cash flow trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
